1423-97-8,MFCD01310349
Catalog No.:AA009F9R

1423-97-8 | estra-1,3,5,7,9-pentaene-3,17beta-diol

Pack Size
Purity
Availability
Price(USD)
Quantity
  
2.5mg
3 weeks  
$466.00   $326.00
- +
10mg
3 weeks  
$1,230.00   $861.00
- +
25mg
3 weeks  
$2,576.00   $1,803.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA009F9R
Chemical Name:
estra-1,3,5,7,9-pentaene-3,17beta-diol
CAS Number:
1423-97-8
Molecular Formula:
C18H20O2
Molecular Weight:
268.3502
MDL Number:
MFCD01310349
SMILES:
Oc1ccc2c(c1)ccc1c2CC[C@]2([C@H]1CC[C@@H]2O)C
Properties
Computed Properties
 
Complexity:
382  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
3  
Defined Bond Stereocenter Count:
0  
Formal Charge:
0  
Heavy Atom Count:
20  
Hydrogen Bond Acceptor Count:
2  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0  
Rotatable Bond Count:
0  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  
XLogP3:
3.8  

Literature

Title: Gene expression analyses of vitellogenin, choriogenin and estrogen receptor subtypes in the livers of male medaka (Oryzias latipes) exposed to equine estrogens.

Journal: Journal of applied toxicology : JAT 20161101

Title: Environmental health impacts of equine estrogens derived from hormone replacement therapy.

Journal: Environmental science & technology 20090515

Title: Structure activity relationships and differential interactions and functional activity of various equine estrogens mediated via estrogen receptors (ERs) ERalpha and ERbeta.

Journal: Endocrinology 20081001

Title: Proliferation of the superficial epithelium of ovaries in senile female rats following oral administration of conjugated equine estrogens.

Journal: Clinics (Sao Paulo, Brazil) 20080601

Title: Select estrogens within the complex formulation of conjugated equine estrogens (Premarin) are protective against neurodegenerative insults: implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer's disease.

Journal: BMC neuroscience 20060101

Title: The estrogen metabolite 17beta-dihydroequilenin counteracts interleukin-1alpha induced expression of inflammatory mediators in human endothelial cells in vitro via NF-kappaB pathway.

Journal: Thrombosis and haemostasis 20060101

Title: Mixtures of estrogenic contaminants in bile of fish exposed to wastewater treatment works effluents.

Journal: Environmental science & technology 20050415

Title: Equine estrogens differentially prevent neuronal cell death induced by glutamate.

Journal: Journal of the Society for Gynecologic Investigation 20030701

Title: Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's.

Journal: The Journal of steroid biochemistry and molecular biology 20030601

Title: Potential role of the interaction between equine estrogens, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) in the prevention of coronary heart and neurodegenerative diseases in postmenopausal women.

Journal: Lipids in health and disease 20030101

Title: Investigations into the biosynthetic pathways for classical and ring B-unsaturated oestrogens in equine placental preparations and allantochorionic tissues.

Journal: The Journal of steroid biochemistry and molecular biology 20021101

Title: Metabolism of equilenin in MCF-7 and MDA-MB-231 human breast cancer cells.

Journal: Chemical research in toxicology 20010501

Title: Differential neuroprotective effects of equine estrogens against oxidized low density lipoprotein-induced neuronal cell death.

Journal: Journal of the Society for Gynecologic Investigation 20010101

Title: Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women.

Journal: Menopause (New York, N.Y.) 20010101

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Historical Records
Tags:1423-97-8 Molecular Formula|1423-97-8 MDL|1423-97-8 SMILES|1423-97-8 estra-1,3,5,7,9-pentaene-3,17beta-diol
Catalog No.: AA009F9R
1423-97-8,MFCD01310349
1423-97-8 | estra-1,3,5,7,9-pentaene-3,17beta-diol
Pack Size: 2.5mg
Purity:
3 weeks
$466.00 $326.00
Pack Size: 10mg
Purity:
3 weeks
$1,230.00 $861.00
Pack Size: 25mg
Purity:
3 weeks
$2,576.00 $1,803.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA009F9R
Chemical Name: estra-1,3,5,7,9-pentaene-3,17beta-diol
CAS Number: 1423-97-8
Molecular Formula: C18H20O2
Molecular Weight: 268.3502
MDL Number: MFCD01310349
SMILES: Oc1ccc2c(c1)ccc1c2CC[C@]2([C@H]1CC[C@@H]2O)C
Properties
Complexity: 382  
Covalently-Bonded Unit Count: 1  
Defined Atom Stereocenter Count: 3  
Defined Bond Stereocenter Count: 0  
Formal Charge: 0  
Heavy Atom Count: 20  
Hydrogen Bond Acceptor Count: 2  
Hydrogen Bond Donor Count: 2  
Isotope Atom Count: 0  
Rotatable Bond Count: 0  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
XLogP3: 3.8  
Literature fold

Title: Gene expression analyses of vitellogenin, choriogenin and estrogen receptor subtypes in the livers of male medaka (Oryzias latipes) exposed to equine estrogens.

Journal: Journal of applied toxicology : JAT20161101

Title: Environmental health impacts of equine estrogens derived from hormone replacement therapy.

Journal: Environmental science & technology20090515

Title: Structure activity relationships and differential interactions and functional activity of various equine estrogens mediated via estrogen receptors (ERs) ERalpha and ERbeta.

Journal: Endocrinology20081001

Title: Proliferation of the superficial epithelium of ovaries in senile female rats following oral administration of conjugated equine estrogens.

Journal: Clinics (Sao Paulo, Brazil)20080601

Title: Select estrogens within the complex formulation of conjugated equine estrogens (Premarin) are protective against neurodegenerative insults: implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer's disease.

Journal: BMC neuroscience20060101

Title: The estrogen metabolite 17beta-dihydroequilenin counteracts interleukin-1alpha induced expression of inflammatory mediators in human endothelial cells in vitro via NF-kappaB pathway.

Journal: Thrombosis and haemostasis20060101

Title: Mixtures of estrogenic contaminants in bile of fish exposed to wastewater treatment works effluents.

Journal: Environmental science & technology20050415

Title: Equine estrogens differentially prevent neuronal cell death induced by glutamate.

Journal: Journal of the Society for Gynecologic Investigation20030701

Title: Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's.

Journal: The Journal of steroid biochemistry and molecular biology20030601

Title: Potential role of the interaction between equine estrogens, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) in the prevention of coronary heart and neurodegenerative diseases in postmenopausal women.

Journal: Lipids in health and disease20030101

Title: Investigations into the biosynthetic pathways for classical and ring B-unsaturated oestrogens in equine placental preparations and allantochorionic tissues.

Journal: The Journal of steroid biochemistry and molecular biology20021101

Title: Metabolism of equilenin in MCF-7 and MDA-MB-231 human breast cancer cells.

Journal: Chemical research in toxicology20010501

Title: Differential neuroprotective effects of equine estrogens against oxidized low density lipoprotein-induced neuronal cell death.

Journal: Journal of the Society for Gynecologic Investigation20010101

Title: Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women.

Journal: Menopause (New York, N.Y.)20010101

Building Blocks More >
1246816-31-8
1246816-31-8
Dimethenamid-d3(4-methyl-d3)
AA009FHJ | MFCD09842641
1346606-50-5
1346606-50-5
Sulfasalazine-d4
AA009FQ3 | MFCD21363838
131030-47-2
131030-47-2
ETHYL 3,4-ETHYLENEDIOXYBENZOYLFORMATE
AA009G68 | MFCD06201701
1227675-51-5
1227675-51-5
(6AS-TRANS)-11-CHLORO-6,6A,7,8,9,13B-HEXAHYDRO-7-METHYL-5H-BENZO[D]NAPHTH[2,1-B]AZEPIN-12-OL HYDROBROMIDE
AA009GMF | MFCD08703109
1346808-44-3
1346808-44-3
3-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole
AA009HI7 | MFCD08166751
1353989-80-6
1353989-80-6
1-(6-(Cyclopropylamino)pyrimidin-4-yl)piperidine-3-carboxylic acid
AA009HX5 | MFCD21098612
138730-81-1
138730-81-1
5-(tert-Butoxycarbonylamino)-1H-indole-2-carboxylic acid
AA009IMD | MFCD16658884
1249603-25-5
1249603-25-5
1-(5-fluoropyridin-3-yl)ethanol
AA009J1I | MFCD14684016
1353637-44-1
1353637-44-1
6-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridine
AA009JS9 | MFCD20926787
1092294-32-0
1092294-32-0
1-Benzyl-N-isopropylpyrrolidin-3-amine
AA009KKT | MFCD10692135
Submit
© 2017 AA BLOCKS, INC. All rights reserved.